<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811586</url>
  </required_header>
  <id_info>
    <org_study_id>HCR-EAST</org_study_id>
    <nct_id>NCT04811586</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of One-Stage Hybrid Coronary Revascularization</brief_title>
  <acronym>HCR-EAST</acronym>
  <official_title>Efficacy and Safety of One-Step Hybrid Coronary Revascularization Versus Percutaneous Coronary Intervention for Patients With Multivessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary revascularization could be accomplished either by percutaneous coronary intervention&#xD;
      (PCI) or coronary artery bypass graft (CABG). PCI with drug-eluting stent (DES) implantation&#xD;
      is featured by minimal invasive, low complication and rapid rehabilitation. CABG is&#xD;
      characterized by improved long-term, event-free survival attributable to the use of left&#xD;
      internal mammary artery (LIMA) graft. Hybrid coronary revascularization (HCR) consists of&#xD;
      LIMA bypass to left anterior coronary descending artery (LAD) by minimal invasive direct&#xD;
      coronary artery bypass (MIDCAB) and PCI of other stenosed coronary arteries with DES&#xD;
      implantation. One-step HCR entails LIMA-LAD anastomosis performed through MIDCAB, immediately&#xD;
      followed by PCI for non-LAD lesions, sometimes for diagonal branch, in the hybrid operating&#xD;
      room. Limited data are available in comparing one-step HCR to PCI alone for the treatment of&#xD;
      multivessel coronary artery disease(MVD). The current EAST-HCR study will investigate the&#xD;
      efficacy and safety of one-step HCR for patients with MVD, as comparing to PCI alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Events (MACCE)</measure>
    <time_frame>2 years</time_frame>
    <description>the occurrence of MACCE at 2 years' clinical follow-up, including all-cause death, myocardial infarction, stroke, and repeated revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>2 years</time_frame>
    <description>individual component of MACCE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital duration (day)</measure>
    <time_frame>up yo 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete revascularization at index hospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>rate of complete revascularization at index hospitalization (defined by Quantitative flow ration[QFR] or Fraction flow reserve[FFR])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis event</measure>
    <time_frame>2 years</time_frame>
    <description>stent thrombosis defined by Academic Research Consortium (ARC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multivessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>one-step Hybrid Coronary Revascularization (HCR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One-step HCR is defined as off-pump MIDCAB LIMA-LAD revascularization immediately followed by PCI for at-least one non-LAD lesion(or LAD-diagonal lesion) with DES implantation in a hybrid operating room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI will be performed using standard technique at the discretion of interventional cardiologist with DES implantation in a routine catheter lab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary revascularization</intervention_name>
    <description>to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)</description>
    <arm_group_label>Percutaneous Coronary Intervention (PCI)</arm_group_label>
    <arm_group_label>one-step Hybrid Coronary Revascularization (HCR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 Years and older&#xD;
&#xD;
          2. signed the informed consent&#xD;
&#xD;
          3. indicated for revascularization, with possible bypass segment in LAD and amendable&#xD;
             lesions by PCI in other vessels&#xD;
&#xD;
          4. anatomy requiring as following: (1) Multivessel CAD involving the LAD (proximal or&#xD;
             mid) and/or LM (ostial, mid-shaft or distal) with at least 1 other epicardial coronary&#xD;
             artery requiring treatment in LCX or RCA, including: (2) LAD disease, and a major&#xD;
             diagonal lesion, either bifurcation or independent in location, with both requiring&#xD;
             revascularization (determined by QFR or FFR) (3) LM distal bifurcation lesion (Medina&#xD;
             1,1,1), intended for 2-stent approach if randomized to PCI&#xD;
&#xD;
          5. Heart team discussion after angiogram, with conclusion of suitable candidate for&#xD;
             either PCI or HCR&#xD;
&#xD;
          6. Able to tolerate and no plans to interrupt dual anti-platelet therapy for 3~12 months&#xD;
&#xD;
          7. Willing to comply with 2-year clinical follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous cardiac or thoracic surgery&#xD;
&#xD;
          2. Previous PCI of the LM and/or LAD within 12 months&#xD;
&#xD;
          3. Totally occluded left main vessel&#xD;
&#xD;
          4. Cardiogenic shock or LVEF &lt;30%&#xD;
&#xD;
          5. Previous STEMI within 30-day prior to randomization&#xD;
&#xD;
          6. Concomitant vascular or other cardiac disease with plan of surgical treatment&#xD;
&#xD;
          7. Indication for chronic oral anticoagulation therapy&#xD;
&#xD;
          8. Previous stroke history within 6-month prior to randomization&#xD;
&#xD;
          9. Survival expectation less than 3 years due to non-cardiac illness&#xD;
&#xD;
         10. Allergy or hypersensitivity to any of the study drugs or devices used in the trial&#xD;
&#xD;
         11. Enrolled in additional clinical study&#xD;
&#xD;
         12. Informed consent not available or noncompliance with follow-up&#xD;
&#xD;
         13. Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi Zhang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qi Zhang, MD, PhD</last_name>
    <phone>+86-21-38804518</phone>
    <email>zhangqnh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Zhang, MD, PhD</last_name>
      <phone>+86-21-38804518</phone>
      <email>zhangqnh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hybrid coronary revascularization (HCR)</keyword>
  <keyword>percutaneous coronary intervention (PCI)</keyword>
  <keyword>coronary artery bypass graft (CABG)</keyword>
  <keyword>multivessel coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

